NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
Clinical Trials
26 trialsNCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT03024437 2025-03-20
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Phase 1/2 Terminated
NCT05087992 2025-02-19
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
Boehringer Ingelheim
Phase 1 Completed
NCT03475004 2024-09-19
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
University of Colorado, Denver
Phase 2 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT02803203 2023-09-22
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT01327612 2021-02-21
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
Amgen
Phase 2 Completed
NCT00281528 2019-11-22
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT01898130 2019-09-17
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Northwestern University
Phase 2 Completed
NCT02069704 2019-07-23
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
mAbxience Research S.L.
Phase 1 Completed
NCT01263782 2019-05-15
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00428922 2018-08-09
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00609765 2017-03-23
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00227019 2017-03-06
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Stanford University
Phase 2 Completed
NCT00537823 2016-12-20
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
Washington University School of Medicine
Phase 2 Terminated
NCT01322815 2016-08-15
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
Georgetown University
Phase 2 Terminated
NCT00390416 2016-03-14
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00468585 2016-01-22
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT00523640 2014-02-11
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
University of Chicago
Phase 2 Terminated
NCT00356122 2011-10-17
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed